Upcoming Earnings:
Estimated EPS
$0.00
Estimated Rev
---
For the full year 2026, Molecular Partners maintains its previously reported forecast with total operating expenses of CHF 45-55 million expected, including approximately CHF 6 million of non-cash effective costs.
Bullish Takeaway
Molecular Partners is advancing its clinical pipeline with the dose escalation of MP0712, the selection of a new CD70 target, and a solid balance sheet expected to fund operations through 2027.
Bearish Takeaway
Molecular Partners incurred a H1 2026 net loss of CHF 26.7 million, experienced a significant decline in cash and shareholders' equity, and remains subject to substantial clinical development and regulatory risks.
Generated by Stocktwits using AI and company-reported earnings data. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|